Enanta Pharmaceuticals Inc. (NASDAQ: ENTA)
$16.11
-0.4300 ( -2.60% ) 157.3K
Enanta Pharmaceuticals Inc is an American biotechnology company focused on the research and development of molecule drugs to cure viral infections and liver diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.
Market Data
Open
$16.11
Previous close
$16.54
Volume
157.3K
Market cap
$342.05M
Day range
$15.75 - $16.66
52 week range
$8.08 - $20.04
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
4 | Insider transactions | 1 | Jul 15, 2024 |
4 | Insider transactions | 1 | Jun 17, 2024 |
10-q | Quarterly Reports | 63 | May 08, 2024 |
8-k | 8K-related | 13 | May 06, 2024 |
3 | Insider transactions | 2 | May 01, 2024 |
4 | Insider transactions | 1 | May 01, 2024 |
8-k | 8K-related | 13 | Mar 12, 2024 |
4 | Insider transactions | 1 | Mar 08, 2024 |
4 | Insider transactions | 1 | Mar 08, 2024 |
4 | Insider transactions | 1 | Mar 08, 2024 |